There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.

The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli Lilly's (NYSE: LLY) popular Mounjaro and Zepbound. However, the U.S. Food and Drug Administration (FDA) recently removed both drugs from its shortage list,

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its shortage list.

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug tirzepatide from its shortage list. Read more here.

Eli Lilly intensifies its legal efforts against compounding pharmacies producing copycat versions of its weight-loss drugs, Mounjaro and Zepbound, after the FDA declares the tirzepatide shortage resolved.

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.